Salvianolic acid Y (TSL 1), a new phenolic acid with the same planar structure as salvianolic acid B, was isolated from Salvia officinalis. The structural elucidation and stereochemistry determination were achieved by spectroscopic and chemical methods, including 1D, 2D-NMR (1H-1H COSY, HMQC and HMBC) and circular dichroism (CD) experiments. The biosynthesis pathway of salvianolic acid B and salvianolic acid Y (TSL 1) was proposed based on structural analysis. The protection of PC12 cells from injury induced by H2O2 was assessed in vitro using a cell viability assay. Salvianolic acid Y (TSL 1) protected cells from injury by 54.2%, which was significantly higher than salvianolic acid B (35.2%).
24 March 2025 in Frontiers in Cell and Developmental Biology
Alzheimer’s disease (AD) is one of the neurodegenerative disorders, characterized by complex pathogenic mechanisms, including the deposition of beta-amyloid protein and hyperphosphorylation of Tau protein. There is currently a lack of effective therapeutic approaches for AD treatment. The aim of this study was to design exosomes (EXO) as a specifically designed carrier able to carry Curcumin (Cur) and Methylene Blue (MB) to improve cognitive function and to elucidate its underlying mechanisms. Our study results indicated that EXO-Cur+MB inhibited Tau protein phosphorylation by activating the AKT/GSK-3β pathway, while reversing cognitive dysfunction in AD mice by reducing apoptosis induced by okadaic acid (OA). Thus, our results suggested that EXO-Cur+MB would be of potential use for the treatment of AD.
Pneumonia is a respiratory disease with high pathogenicity and mortality. Traditional Chinese medicine (TCM) is a natural therapy that has proven effectiveness and safety. Although TCM has been found to be effective in treating pneumonia, further research is needed to determine the specific mechanism of action. This paper presents a literature search conducted in PubMed, Web of Science, and China National Knowledge Infrastructure (CNKI) databases using the keywords “pneumonia” and “network pharmacology.” After screening, we retained the literature related to TCM. The study found that, according to network pharmacology prediction, 4 types of TCMs–natural active compounds, single herb medicine, Chinese patent medicines, and multi-component herbal formulations–were effective in treating pneumonia. TCM components demonstrated a multi-target and multi-pathway approach to treat the disease. The diversity of targets and signaling pathways not only facilitates the investigation of TCM’s mechanism of action of TCM in pneumonia treatment but also offers novel insights and perspectives for innovative drug research and development.
A well‐established mechanism of action for managing pneumonia using Glycyrrhiza is unknown. Using network pharmacology and molecular docking simulations, we investigated the mechanism of action of Glycyrrhiza against pneumonia. To identify the targets of the active components of Glycyrrhiza from the Traditional Chinese Medicine Systems Pharmacology database, oral bioavailability and drug likeness were utilized as indicators. Pneumonia‐associated genes were identified and screened from the databases. Integrated analysis was conducted to elucidate the relationship between the active components of Glycyrrhiza and intersecting genes; a comprehensive Glycyrrhiza active component‐target gene relationship map was constructed. Intersecting genes underwent Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses to examine their biological functions. A protein–protein interaction network map was constructed to identify hub genes. Molecular docking simulations were performed to investigate binding interactions between hub genes and their corresponding active components. Of the 96 overlapping genes, topological analysis revealed 10 hub genes. Glycyrrhiza exerts therapeutic effects through a multi‐target and multipathway approach, suggesting a synergistic treatment for pneumonia. MAPK14 showed a favorable binding affinity with most of the active compounds, indicating that MAPK14 and related compounds in Glycyrrhiza have development potential.
Asthma affects approximately 260 million people globally and causes an estimated 450,000 deaths annually, posing a serious threat to human health and life quality. Current mainstay pharmacotherapies are effective for symptom control but are associated with well-documented systemic side effects and do not offer a cure. Flavonoids have garnered increasing scientific interest due to their pleiotropic biological activities; however, there is still a lack of summary on the mechanism of flavonoids in key pathological processes of asthma. This review summarizes the evidence on how flavonoids modulate key asthma pathologies, covering airway inflammation, T cell subset imbalance, airway remodeling, and smooth muscle contractility. However, clinical translation is severely constrained by poor solubility, rapid metabolism, and low oral bioavailability. Flavonoids exhibit multi-target therapeutic potential for asthma, but well-designed, large-scale clinical trials are necessary to validate these preclinical observations.